Research suggests drug improves stem cell transplants for those with multiple myeloma
Researchers in the US have shed light on a way to carry out stem cell transplants in people with multiple myeloma more efficiently, using a drug called motixafortide. The scientific journal, Nature Medicine, published the findings, today (Monday 17 April).
What our Deputy Director of Research, Sarah McDonald said:
Patients with multiple myeloma often receive a stem cell transplant as part of their treatment, however the number of cells taken and can be used for this treatment is often low, impacting patient outcomes in what can already be a challenging experience.
“In this late phase clinical trial in the US, researchers found the experimental drug motixafortide when used alongside the existing treatment approach increases the number of stem cells that can be taken and used, helping improve the likelihood of success for a patient.
“This new approach still needs regulatory approval, but with no cure for myeloma and the high likelihood of treatment relapse, improving stem cell transplants is vitally important With only 14% of people realising myeloma is a type of blood cancer, we must make sure it is not forgotten when it comes to research funding.“
What did the study find?
The phase 3 clinical trial suggests motixafortide works well in combination with the standard drug, granulocyte colony stimulating factor (G-CSF), in getting stem cells in patients with multiple myeloma mobilized.
It allowed optimal numbers of stem cells to be harvested in over 9 in 10 of patients after two collection procedures, compared with just over 1 in 4 of patients who received G-CSF plus a dummy drug.
The study also found that the combination worked quickly and was generally well-tolerated.
Stem cells mobilized by motixafortide also showed increased expression of genes and genetic pathways associated with self-renewal and regeneration, all beneficial for increased effectiveness of a stem cell transplant.